Background Breast cancer (BC) is considered one of the most frequent cancers worldwide. Eyes absent homolog 2 (EYA2) plays a crucial role in promoting cancer proliferation in many tissues, including the breast. Negative EYA2 expression in BC has been associated with aggressive tumors and poor prognosis. Aim This study aimed to investigate the immunohistochemical expressions of EYA2 and its relationship with different clinicopathological parameters, molecular types, and to evaluate their prognostic significance further. Patients and Methods Immunohistochemical expressions of EYA2 were examined in 60 randomly selected cases of invasive duct carcinoma. Results Positive EYA2 immunostaining was detected in 40% of cases and showed significant associations with higher tumor grade ( P =0.029), stage ( P <0.001), nodal spread ( P =0.002), estrogen-receptor negative ( P <0.001), Progesterone-receptor negative ( P <0.001), and higher Nottingham Prognostic Index ( P <0.001). No significant relationship was found between EYA2 expression and some clinicopathological parameters, including age, size, and human epidermal growth receptor-2 expression. Loss of EYA2 expression was observed frequently in luminal A ( P <0.001) and luminal B subgroups ( P <0.001). Correlation analysis between EYA2 and estrogen-receptor expressions showed a highly statistically significant negative correlation ( P <0.001 and r =−0.720). Univariate survival analyses demonstrated that cases with positive EYA2 expression had a significantly worse prognosis than those with negative (Log rank P =0.0000). Altogether, our findings suggest that EYA2 can serve as a possible bad prognostic biomarker in BC. Conclusion EYA2 was associated significantly with unfavorable prognostic parameters and was correlated with shorter survival among breast cancer cases.
Toni et al. (Tue,) studied this question.